CRESO PHARMA LIMITED CPH

CPHASX
CPH
CRESO PHARMA LIMITEDASX
 
No trades
Upcoming Earnings
EPS
Market Cap
Div Yield
P/E
Upcoming Earnings
EPS
Market Cap
Div Yield
P/E
Valuation
Enterprise Value/EBITDA, TTM
Enterprise Value, FQ
Market Cap — Basic
Number of Employees
Number of Shareholders
Price/Earnings, TTM
Price/Revenue, TTM
Price/Book Ratio, FY
Price/Sales Ratio, FY
Balance Sheet
Current Ratio, FQ
Debt to Equity, FQ
Net Debt, FQ
Quick Ratio, FQ
Total Assets, FQ
Total Debt, FQ
Operating Metrics
Return on Assets, TTM
Return on Equity, TTM
Return on Invested Capital, TTM
Revenue per Employee, TTM
Price History
Average Volume (10 day)
Beta - 1 Year
Price - 52 Week High
Price - 52 Week Low
Dividends
Dividends Paid, FY
Dividends per Share, FY
Expected Annual Dividends
Dividends Yield
Margins
Net Margin, TTM
Gross Margin, TTM
Operating Margin, TTM
Pretax Margin, TTM
Income Statement
Basic EPS, Net Income
Earnings per Share, Basic, TTM
EBITDA, TTM
Gross Profit, FY
Last Annual EPS
Last Annual Revenue, FY
Net Income, FY
Total Revenue, FY
Free Cash Flow, TTM

Profile

Sector: Health Technology
Industry: Pharmaceuticals: Major
Creso Pharma Ltd. develops, registers and commercializes pharmaceutical-grade cannabis and hemp-hemp-derived therapeutic, nutraceutical, and lifestyle products with wide patient and consumer reach for human and animal health. It operates through the following segments: Creso Pharma Switzerland GmbH in Switzerland, Kunna S.A.S. located in Colombia, Creso Pharma Limited in Australia and other. The company was founded by Adam Blumenthal, Miri Halperin Wernli and Boaz Wachtel on November 20, 2015 and is headquartered in Nedlends, Australia.